IGM Biosciences (IGMS) Revenue & Revenue Breakdown
IGM Biosciences Revenue Highlights
Latest Revenue (Y)
$2.13M
Latest Revenue (Q)
$516.00K
IGM Biosciences Revenue by Period
IGM Biosciences Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $2.13M | 99.25% |
2022-12-31 | $1.07M | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | - |
IGM Biosciences Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $516.00K | -58.85% |
2024-06-30 | $1.25M | 152.31% |
2024-03-31 | $497.00K | -23.66% |
2023-12-31 | $651.00K | 27.90% |
2023-09-30 | $509.00K | 13.62% |
2023-06-30 | $448.00K | -14.18% |
2023-03-31 | $522.00K | 40.32% |
2022-12-31 | $372.00K | 12.39% |
2022-09-30 | $331.00K | -9.56% |
2022-06-30 | $366.00K | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
IGM Biosciences Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
RVMD | Revolution Medicines | $11.58M | - |
RNA | Avidity Biosciences | $9.56M | $2.04M |
IKNA | Ikena Oncology | $9.16M | - |
STOK | Stoke Therapeutics | $8.78M | $4.89M |
IGMS | IGM Biosciences | $2.13M | $516.00K |
DSGN | Design Therapeutics | - | - |
CGEM | Cullinan Oncology | - | - |
BDTX | Black Diamond Therapeutics | - | - |
ERAS | Erasca | - | - |
PASG | Passage Bio | - | - |
MLYS | Mineralys Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | $4.70M |